Stock Track | JD Health Plummets 5.31% Intraday on GLP-1 Drug Sales Regulations and Sector Weakness

Stock Track10:02

JD Health's stock plummeted 5.31% during intraday trading on Monday, as new regulations on online sales of GLP-1 weight loss drugs and broad sector weakness pressured the online healthcare platform.

New regulations that took effect require purchasers of GLP-1 weight loss drugs to present paper prescriptions issued by physical hospitals, invalidating prescriptions from internet hospitals. This has led multiple pharmacies to delist related products from JD and other platforms, directly suppressing the company's online pharmaceutical sales business.

The Internet and Direct Marketing Retail sector faced broad selling pressure, with peers including Ali Health, PA Good Doctor, JD Group, Alibaba, and Meituan also declining, amplifying the downward move in JD Health's shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment